U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. E2E Pharmacovigilance Planning
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

E2E Pharmacovigilance Planning March 2005

Final
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research

This guidance is intended to aid in planning pharmacovigilance activities, especially in
preparation for the early postmarketing period of a new drug (in this guidance, the term drug
denotes chemical entities, biotechnology-derived products, and vaccines).  The main focus of this
guidance is on a safety specification and pharmacovigilance plan that might be submitted at the
time of license application. The guidance can be used by sponsors to develop a stand-alone document
for regions that prefer this approach or to provide guidance on incorporation of elements of the
safety specification and pharmacovigilance plan into the Common Technical Document (CTD).
 


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.